State of Alaska Department of Revenue cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Monday. A ...

Deutsche Bank (ETR:DBKGn) began coverage on Neurocrine Biosciences (NASDAQ:NBIX) stock, assigning a Hold rating and setting a price target of $138. The bank's analyst noted that with a current market ...

Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Investing.com -- Shares of Neurocrine (NASDAQ: NBIX) Biosciences (NASDAQ: NBIX) tumbled 11% as the company reported revenues that fell short of estimates. Despite reporting a 26% growth in INGREZZA® ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...